GALECTIN THERAPEUTICS INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
GALECTIN THERAPEUTICS INC. (GALT) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.15 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2025-03-31
- GALECTIN THERAPEUTICS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-12-31 was $590.00K, a 18.71% increase year-over-year.
- GALECTIN THERAPEUTICS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-09-30 was $515.00K, a 0.19% decline year-over-year.
- GALECTIN THERAPEUTICS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-06-30 was $738.00K, a 43.02% increase year-over-year.
- GALECTIN THERAPEUTICS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-03-31 was $303.00K, a 57.68% decline year-over-year.
- GALECTIN THERAPEUTICS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $2.15M, a 7.30% decline from fiscal 2023.
- GALECTIN THERAPEUTICS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $2.31M, a 24.52% decline from fiscal 2022.
- GALECTIN THERAPEUTICS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $3.07M, a 43.59% increase from fiscal 2021.
- GALECTIN THERAPEUTICS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $2.14M, a 18.73% increase from fiscal 2020.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 138 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 150 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 162 month |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | $590.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.10M derived: sum of 2 quarters · filed 2025-03-31 | $1.84M derived: sum of 3 quarters · filed 2025-03-31 | $2.15M 10-K · filed 2025-03-31 | |||||
| 2024-09-30 | $515.00K 10-Q · filed 2024-11-14 | $1.25M derived: sum of 2 quarters · filed 2024-11-14 | $1.56M 10-Q · filed 2024-11-14 | $2.05M derived: sum of 4 quarters · filed 2025-03-31 | |||||
| 2024-06-30 | $738.00K 10-Q · filed 2024-08-13 | $1.04M 10-Q · filed 2024-08-13 | $1.54M derived: sum of 3 quarters · filed 2025-03-31 | $2.05M derived: sum of 4 quarters · filed 2025-03-31 | |||||
| 2024-03-31 | $303.00K derived: 10-K 12 month − 3 quarters · filed 2025-03-31 | $800.00K derived: sum of 2 quarters · filed 2025-03-31 | $1.32M derived: sum of 3 quarters · filed 2025-03-31 | $1.83M derived: sum of 4 quarters · filed 2025-03-31 | |||||
| 2023-12-31 | $497.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.01M derived: sum of 2 quarters · filed 2025-03-31 | $1.53M derived: sum of 3 quarters · filed 2025-03-31 | $2.31M 10-K · filed 2025-03-31 | |||||
| 2023-09-30 | $516.00K 10-Q · filed 2024-11-14 | $586.00K 10-Q · filed 2023-11-13 | $1.03M derived: sum of 2 quarters · filed 2024-11-14 | $1.82M 10-Q · filed 2024-11-14 | $2.43M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2023-06-30 | $516.00K 10-Q · filed 2024-08-13 | $1.23M 10-Q · filed 2024-08-13 | $1.91M derived: sum of 3 quarters · filed 2024-08-13 | $2.59M derived: sum of 4 quarters · filed 2024-08-13 | |||||
| 2023-03-31 | $716.00K 10-Q · filed 2023-05-15 | $1.40M derived: sum of 2 quarters · filed 2024-03-29 | $2.08M derived: sum of 3 quarters · filed 2024-03-29 | $2.73M derived: sum of 4 quarters · filed 2024-03-29 | |||||
| 2022-12-31 | $681.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $1.36M derived: sum of 2 quarters · filed 2024-03-29 | $2.01M derived: sum of 3 quarters · filed 2024-03-29 | $3.07M 10-K · filed 2024-03-29 | |||||
| 2022-09-30 | $681.00K 10-Q · filed 2023-11-13 | $1.33M derived: sum of 2 quarters · filed 2023-11-13 | $2.39M 10-Q · filed 2023-11-13 | $2.19M 10-Q · filed 2022-11-14 | $3.04M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | $647.00K 10-Q · filed 2023-08-14 | $1.71M 10-Q · filed 2023-08-14 | $2.36M derived: sum of 3 quarters · filed 2023-08-14 | $2.95M derived: sum of 4 quarters · filed 2023-08-14 | |||||
| 2022-03-31 | $1.06M 10-Q · filed 2023-05-15 | $1.71M derived: sum of 2 quarters · filed 2023-05-15 | $2.30M derived: sum of 3 quarters · filed 2023-05-15 | $2.88M derived: sum of 4 quarters · filed 2023-05-15 | |||||
| 2021-12-31 | $654.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $1.24M derived: sum of 2 quarters · filed 2023-03-30 | $1.82M derived: sum of 3 quarters · filed 2023-03-30 | $2.14M 10-K · filed 2023-03-30 | |||||
| 2021-09-30 | $587.00K 10-Q · filed 2022-11-14 | $1.17M derived: sum of 2 quarters · filed 2022-11-14 | $1.48M 10-Q · filed 2022-11-14 | $2.05M derived: sum of 4 quarters · filed 2022-11-14 | |||||
| 2021-06-30 | $581.00K 10-Q · filed 2022-08-15 | $895.00K 10-Q · filed 2022-08-15 | $1.46M derived: sum of 3 quarters · filed 2022-08-15 | $1.87M derived: sum of 4 quarters · filed 2022-08-15 | |||||
| 2021-03-31 | $314.00K 10-Q · filed 2022-05-16 | $881.00K derived: sum of 2 quarters · filed 2022-05-16 | $1.29M derived: sum of 3 quarters · filed 2022-05-16 | $1.68M derived: sum of 4 quarters · filed 2022-05-16 | |||||
| 2020-12-31 | $567.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $975.00K derived: sum of 2 quarters · filed 2022-03-31 | $1.37M derived: sum of 3 quarters · filed 2022-03-31 | $1.80M 10-K · filed 2022-03-31 | |||||
| 2020-09-30 | $408.00K 10-Q · filed 2021-11-15 | $802.00K derived: sum of 2 quarters · filed 2021-11-15 | $1.23M 10-Q · filed 2021-11-15 | $1.65M derived: sum of 4 quarters · filed 2021-11-15 | |||||
| 2020-06-30 | $394.00K 10-Q · filed 2021-08-16 | $824.00K 10-Q · filed 2021-08-16 | $1.24M derived: sum of 3 quarters · filed 2021-08-16 | $1.65M derived: sum of 4 quarters · filed 2021-08-16 | |||||
| 2020-03-31 | $430.00K 10-Q · filed 2021-05-17 | $844.00K derived: sum of 2 quarters · filed 2021-05-17 | $1.26M derived: sum of 3 quarters · filed 2021-05-17 | $1.70M derived: sum of 4 quarters · filed 2021-05-17 | |||||
| 2019-12-31 | $414.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $828.00K derived: sum of 2 quarters · filed 2021-03-31 | $1.27M derived: sum of 3 quarters · filed 2021-03-31 | $1.68M 10-K · filed 2021-03-31 | |||||
| 2019-09-30 | $414.00K 10-Q · filed 2020-11-09 | $857.00K derived: sum of 2 quarters · filed 2020-11-09 | $1.27M 10-Q · filed 2020-11-09 | $2.42M derived: sum of 4 quarters · filed 2020-11-09 | |||||
| 2019-06-30 | $443.00K 10-Q · filed 2020-08-10 | $855.00K 10-Q · filed 2020-08-10 | $2.01M derived: sum of 3 quarters · filed 2020-08-10 | $2.67M derived: sum of 4 quarters · filed 2020-08-10 | |||||
| 2019-03-31 | $412.00K 10-Q · filed 2020-05-11 | $1.56M derived: sum of 2 quarters · filed 2020-05-11 | $2.23M derived: sum of 3 quarters · filed 2020-05-11 | $3.67M derived: sum of 4 quarters · filed 2020-05-11 | |||||
| 2018-12-31 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $1.81M derived: sum of 2 quarters · filed 2020-03-16 | $3.26M derived: sum of 3 quarters · filed 2020-03-16 | $4.45M 10-K · filed 2020-03-16 | |||||
| 2018-09-30 | $663.00K 10-Q · filed 2019-11-12 | $2.11M derived: sum of 2 quarters · filed 2019-11-12 | $3.29M 10-Q · filed 2019-11-12 | ||||||
| 2018-06-30 | $1.44M 10-Q · filed 2019-08-09 | $2.63M 10-Q · filed 2019-08-09 | |||||||
| 2018-03-31 | $1.19M 10-Q · filed 2019-05-10 | ||||||||
| 2017-12-31 | $1.10M 10-K · filed 2019-03-06 | ||||||||
| 2016-12-31 | $2.48M 10-K · filed 2018-03-29 | ||||||||
| 2015-12-31 | $3.33M 10-K · filed 2017-03-28 | ||||||||
| 2014-12-31 | $3.97M 10-K · filed 2016-03-15 | ||||||||
| 2013-12-31 | $513.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $2.32M derived: sum of 2 quarters · filed 2016-03-15 | $2.94M derived: sum of 3 quarters · filed 2016-03-15 | $3.79M 10-K · filed 2016-03-15 | $15.42M 10-K · filed 2014-03-21 | ||||
| 2013-09-30 | $1.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $2.42M derived: sum of 2 quarters · filed 2013-11-12 | $3.28M 10-Q · filed 2013-11-12 | $3.90M derived: sum of 4 quarters · filed 2015-03-18 | |||||
| 2013-06-30 | $615.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14 | $1.47M 10-Q · filed 2013-08-14 | $2.09M derived: sum of 3 quarters · filed 2015-03-18 | $2.90M derived: sum of 4 quarters · filed 2015-03-18 | |||||
| 2013-03-31 | $852.00K 10-Q · filed 2013-05-10 | $1.47M derived: sum of 2 quarters · filed 2015-03-18 | $2.28M derived: sum of 3 quarters · filed 2015-03-18 | $3.15M derived: sum of 4 quarters · filed 2015-03-18 | |||||
| 2012-12-31 | $622.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-18 | $1.43M derived: sum of 2 quarters · filed 2015-03-18 | $2.29M derived: sum of 3 quarters · filed 2015-03-18 | $2.77M 10-K · filed 2015-03-18 | $11.63M 10-K · filed 2013-03-29 | ||||
| 2012-09-30 | $808.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $1.67M derived: sum of 2 quarters · filed 2012-11-09 | $2.14M 10-Q · filed 2012-11-09 | $2.70M derived: sum of 4 quarters · filed 2013-03-29 | |||||
| 2012-06-30 | $863.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-10 | $1.34M 10-Q · filed 2012-08-10 | $1.89M derived: sum of 3 quarters · filed 2013-03-29 | $2.54M derived: sum of 4 quarters · filed 2013-03-29 | |||||
| 2012-03-31 | $473.00K 10-Q · filed 2012-05-11 | $1.03M derived: sum of 2 quarters · filed 2013-03-29 | $1.68M derived: sum of 3 quarters · filed 2013-03-29 | ||||||
| 2011-12-31 | $557.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-29 | $1.21M derived: sum of 2 quarters · filed 2013-03-29 | $3.25M 10-K · filed 2013-03-29 | $8.87M 10-K · filed 2012-03-30 | |||||
| 2011-09-30 | $649.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-10 | $2.69M 10-Q · filed 2011-11-10 | |||||||
| 2011-06-30 | $2.04M 10-Q · filed 2011-08-12 | ||||||||
| 2010-12-31 | $1.94M 10-K · filed 2012-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |